Loading...
XNAS
MEDP
Market cap15bUSD
Dec 04, Last price  
544.77USD
1D
-5.50%
1Q
11.87%
Jan 2017
1,410.31%
IPO
1,842.83%
Name

Medpace Holdings Inc

Chart & Performance

D1W1MN
XNAS:MEDP chart
P/E
37.95
P/S
7.28
EPS
14.36
Div Yield, %
Shrs. gr., 5y
-3.15%
Rev. gr., 5y
19.62%
Revenues
2.11b
+11.84%
272,890,000290,041,000359,059,000421,582,000436,152,000704,589,000860,969,000925,925,0001,142,377,0001,459,996,0001,885,842,0002,109,054,000
Net income
404m
+42.99%
24,844,000-15,572,000-8,673,00013,392,00039,032,00072,894,000100,164,000144,925,000181,390,000245,211,000282,810,000404,386,000
CFO
609m
+40.48%
98,142,00075,202,00084,117,00091,732,00097,385,000156,584,000201,867,000258,676,000263,327,000388,050,000433,374,000608,815,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
IPO date
Aug 11, 2016
Employees
5,600
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT